Wang Liang

Filings by Wang Liang span 3 companies, the busiest being Touyun Biotech Group Ltd., Mediwelcome Healthcare Management & Technology Inc. and Republic Healthcare Ltd. Between 12 December 2017 and 10 September 2025, the trades on record add up to 11 filings.

In open-market terms, that means 6 purchases worth €6.0M on one side and 2 sales on the other. The totals do not cover 4 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 2025 to date brings 2 purchases and no sales.

In size, the median ticket on the buying side is €342k. Clusters matter here: 1 out of 4 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Ninety days after publication, 4 purchases show a median change of -17.2%, with the price up in 25% of them. These figures describe past trades and do not predict future prices.

The newest entry dates from 11 September 2025: an open-market purchase of €81k, in Republic Healthcare Ltd. Filings reach the HKEX feed a median of 4 days after the trade. Until a filing is published, the market cannot know about the trade. This summary is built from HKEX disclosures alone and does not predict where the share price will go.